Validation of a Clinical-Grade Assay to Measure Donor-Derived Cell-Free DNA in Solid Organ Transplant Recipients

Journal of Molecular Diagnostics

Volumn 18, Issue 6, 2016, Pages 890-902

  Grskovic, Marica ^a   Hiller, David J ^a   Eubank, Lane A ^a   Sninsky, John J ^a   Christopherson, Cindy ^a   Collins, John P ^a   Thompson, Kathryn ^a   Song, Mindy ^a   Wang, Yue S ^a   Ross, David ^a   Nelles, Mitchell J ^a   Yee, James P ^a   Wilber, Judith C ^a   Crespo Leiro, Maria G ^b   Scott, Susan L ^a   Woodward, Robert N ^a  

^a CareDx   (United States)

^b University Hospital of Corunna   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BIOPSY; DNA DETERMINATION; GENE FREQUENCY; GENE MUTATION; GENOME; GENOTYPE; GRAFT RECIPIENT; HEART GRAFT; HUMAN; HUMAN TISSUE; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; NEXT GENERATION SEQUENCING; ORGAN CULTURE; QUANTITATIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; TURNAROUND TIME; VALIDATION PROCESS; ALLELE; BLOOD; CELL LINE; DONOR; FEMALE; GENETIC MARKER; GENETIC SCREENING; GENETICS; GRAFT REJECTION; HIGH THROUGHPUT SEQUENCING; IMMUNOLOGY; MALE; ORGAN TRANSPLANTATION; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STANDARD; STANDARDS;

DNA; GENETIC MARKER;

ALLELES; CELL LINE; DNA; FEMALE; GENE FREQUENCY; GENETIC MARKERS; GENETIC TESTING; GENOTYPE; GRAFT REJECTION; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; ORGAN TRANSPLANTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TISSUE DONORS; TRANSPLANT RECIPIENTS;

EID: 84992359593     PISSN: 15251578     EISSN: 19437811     Source Type: Journal    
DOI: 10.1016/j.jmoldx.2016.07.003     Document Type: Article

References (32)

1. 1 Wong, F.C., Lo, Y.M., Prenatal diagnosis innovation: genome sequencing of maternal plasma. Annu Rev Med 67 (2016), 419–432.
2. 2 Alix-Panabieres, C., Pantel, K., Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov 6 (2016), 479–491.
3. 3 Gold, B., Cankovic, M., Furtado, L.V., Meier, F., Gocke, C.D., Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility?. J Mol Diagn 17 (2015), 209–224.
4. 4 Gielis, E.M., Ledeganck, K.J., De Winter, B.Y., Del Favero, J., Bosmans, J.L., Claas, F.H., Abramowicz, D., Eikmans, M., Cell-free DNA: an upcoming biomarker in transplantation. Am J Transplant 15 (2015), 2541–2551.
5. 5 Lo, Y.M.D., Tein, M.S.C., Pang, C.C.P., Yeung, C.K., Tong, K.L., Hjelm, N.M., Presence of donor-specific DNA in plasma of kidney and liver-transplant recipients. Lancet 351 (1998), 1329–1330.
6. 6 Garcia Moreira, V., Prieto Garcia, B., Baltar Martin, J.M., Ortega Suarez, F., Alvarez, F.V., Cell-free DNA as a noninvasive acute rejection marker in renal transplantation. Clin Chem 55 (2009), 1958–1966.
7. 7 De Vlaminck, I., Valantine, H.A., Snyder, T.M., Strehl, C., Cohen, G., Luikart, H., Neff, N.F., Okamoto, J., Bernstein, D., Weisshaar, D., Quake, S.R., Khush, K.K., Circulating cell-free DNA enables noninvasive diagnosis of heart transplant rejection. Sci Transl Med, 6, 2014, 241ra77.
8. 8 Snyder, T.M., Khush, K.K., Valantine, H.A., Quake, S.R., Universal noninvasive detection of solid organ transplant rejection. Proc Natl Acad Sci U S A 108 (2011), 6229–6234.
9. 9 Beck, J., Bierau, S., Balzer, S., Andag, R., Kanzow, P., Schmitz, J., Gaedcke, J., Moerer, O., Slotta, J.E., Walson, P., Kollmar, O., Oellerich, M., Schutz, E., Digital droplet PCR for rapid quantification of donor DNA in the circulation of transplant recipients as a potential universal biomarker of graft injury. Clin Chem 59 (2013), 1732–1741.
10. 10 Hidestrand, M., Tomita-Mitchell, A., Hidestrand, P.M., Oliphant, A., Goetsch, M., Stamm, K., Liang, H.L., Castleberry, C., Benson, D.W., Stendahl, G., Simpson, P.M., Berger, S., Tweddell, J.S., Zangwill, S., Mitchell, M.E., Highly sensitive noninvasive cardiac transplant rejection monitoring using targeted quantification of donor-specific cell-free deoxyribonucleic acid. J Am Coll Cardiol 63 (2014), 1224–1226.
11. 11 De Vlaminck, I., Martin, L., Kertesz, M., Patel, K., Kowarsky, M., Strehl, C., Cohen, G., Luikart, H., Neff, N.F., Okamoto, J., Nicolls, M.R., Cornfield, D., Weill, D., Valantine, H., Khush, K.K., Quake, S.R., Noninvasive monitoring of infection and rejection after lung transplantation. Proc Natl Acad Sci U S A 112 (2015), 13336–13341.
12. 12 Gadi, V.K., Nelson, J.L., Boespflug, N.D., Guthrie, K.A., Kuhr, C.S., Soluble donor DNA concentrations in recipient serum correlate with pancreas-kidney rejection. Clin Chem 52 (2006), 379–382.
13. 13 Macher, H.C., Suarez-Artacho, G., Guerrero, J.M., Gomez-Bravo, M.A., Alvarez-Gomez, S., Bernal-Bellido, C., Dominguez-Pascual, I., Rubio, A., Monitoring of transplanted liver health by quantification of organ-specific genomic marker in circulating DNA from receptor. PLoS One, 9, 2014, e113987.
14. 14 Sigdel, T.K., Vitalone, M.J., Tran, T.Q., Dai, H., Hsieh, S.C., Salvatierra, O., Sarwal, M.M., A rapid noninvasive assay for the detection of renal transplant injury. Transplantation 96 (2013), 97–101.
15. 15 Zhang, J., Tong, K.L., Li, P.K., Chan, A.Y., Yeung, C.K., Pang, C.C., Wong, T.Y., Lee, K.C., Lo, Y.M., Presence of donor- and recipient-derived DNA in cell-free urine samples of renal transplantation recipients: urinary DNA chimerism. Clin Chem 45 (1999), 1741–1746.
16. 16 Bruno, D.L., Ganesamoorthy, D., Thorne, N.P., Ling, L., Bahlo, M., Forrest, S., Veenendaal, M., Katerelos, M., Skene, A., Ierino, F.L., Power, D.A., Slater, H.R., Use of copy number deletion polymorphisms to assess DNA chimerism. Clin Chem 60 (2014), 1105–1114.
17. 17 Oellerich, M., Schutz, E., Kanzow, P., Schmitz, J., Beck, J., Kollmar, O., Streit, F., Walson, P.D., Use of graft-derived cell-free DNA as an organ integrity biomarker to reexamine effective tacrolimus trough concentrations after liver transplantation. Ther Drug Monit 36 (2014), 136–140.
18. 18 Beck, J., Oellerich, M., Schulz, U., Schauerte, V., Reinhard, L., Fuchs, U., Knabbe, C., Zittermann, A., Olbricht, C., Gummert, J.F., Shipkova, M., Birschmann, I., Wieland, E., Schutz, E., Donor-derived cell-free DNA is a novel universal biomarker for allograft rejection in solid organ transplantation. Transplant Proc 47 (2015), 2400–2403.
19. 19 Pakstis, A.J., Speed, W.C., Fang, R., Hyland, F.C., Furtado, M.R., Kidd, J.R., Kidd, K.K., SNPs for a universal individual identification panel. Hum Genet 127 (2010), 315–324.
20. 20 Clinical and Laboratory Standards Institute (CLSI). Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures: Approved Guideline. CLSI document EP17-A2, ed 2, 2012, Clinical and Laboratory Standards Institute, Wayne, PA.
21. 21 Stewart, S., Winters, G.L., Fishbein, M.C., Tazelaar, H.D., Kobashigawa, J., Abrams, J., Andersen, C.B., Angelini, A., Berry, G.J., Burke, M.M., Demetris, A.J., Hammond, E., Itescu, S., Marboe, C.C., McManus, B., Reed, E.F., Reinsmoen, N.L., Rodriguez, E.R., Rose, A.G., Rose, M., Suciu-Focia, N., Zeevi, A., Billingham, M.E., Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 24 (2005), 1710–1720.
22. 22 Crespo-Leiro, M.G., Zuckermann, A., Bara, C., Mohacsi, P., Schulz, U., Boyle, A., Ross, H.J., Parameshwar, J., Zakliczynski, M., Fiocchi, R., Stypmann, J., Hoefer, D., Lehmkuhl, H., Deng, M.C., Leprince, P., Berry, G., Marboe, C.C., Stewart, S., Tazelaar, H.D., Baron, H.M., Coleman, I.C., Vanhaecke, J., Concordance among pathologists in the second Cardiac Allograft Rejection Gene Expression Observational Study (CARGO II). Transplantation 94 (2012), 1172–1177.
23. 23 Marboe, C.C., Billingham, M., Eisen, H., Deng, M.C., Baron, H., Mehra, M., Hunt, S., Wohlgemuth, J., Mahmood, I., Prentice, J., Berry, G., Nodular endocardial infiltrates (Quilty lesions) cause significant variability in diagnosis of ISHLT Grade 2 and 3A rejection in cardiac allograft recipients. J Heart Lung Transplant 24 (2005), S219–S226.
24. 24 Rehm, H.L., Bale, S.J., Bayrak-Toydemir, P., Berg, J.S., Brown, K.K., Deignan, J.L., Friez, M.J., Funke, B.H., Hegde, M.R., Lyon, E., Working Group of the American College of Medical Genetics and Genomics Laboratory Quality Assurance Committee. ACMG clinical laboratory standards for next-generation sequencing. Genet Med 15 (2013), 733–747.
25. 25 Aziz, N., Zhao, Q., Bry, L., Driscoll, D.K., Funke, B., Gibson, J.S., Grody, W.W., Hegde, M.R., Hoeltge, G.A., Leonard, D.G., Merker, J.D., Nagarajan, R., Palicki, L.A., Robetorye, R.S., Schrijver, I., Weck, K.E., Voelkerding, K.V., College of American Pathologists’ laboratory standards for next-generation sequencing clinical tests. Arch Pathol Lab Med 139 (2015), 481–493.
26. 26 McShane, L.M., Cavenagh, M.M., Lively, T.G., Eberhard, D.A., Bigbee, W.L., Williams, P.M., Mesirov, J.P., Polley, M.Y., Kim, K.Y., Tricoli, J.V., Taylor, J.M., Shuman, D.J., Simon, R.M., Doroshow, J.H., Conley, B.A., Criteria for the use of omics-based predictors in clinical trials. Nature 502 (2013), 317–320.
27. 27 Pritchard, C.C., Salipante, S.J., Koehler, K., Smith, C., Scroggins, S., Wood, B., Wu, D., Lee, M.K., Dintzis, S., Adey, A., Liu, Y., Eaton, K.D., Martins, R., Stricker, K., Margolin, K.A., Hoffman, N., Churpek, J.E., Tait, J.F., King, M.C., Walsh, T., Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens. J Mol Diagn 16 (2014), 56–67.
28. 28 Spencer, D.H., Tyagi, M., Vallania, F., Bredemeyer, A.J., Pfeifer, J.D., Mitra, R.D., Duncavage, E.J., Performance of common analysis methods for detecting low-frequency single nucleotide variants in targeted next-generation sequence data. J Mol Diagn 16 (2014), 75–88.
29. 29 Schirmer, M., Ijaz, U.Z., D'Amore, R., Hall, N., Sloan, W.T., Quince, C., Insight into biases and sequencing errors for amplicon sequencing with the Illumina MiSeq platform. Nucleic Acids Res, 43, 2015, e37.
30. 30 Sehn, J.K., Spencer, D.H., Pfeifer, J.D., Bredemeyer, A.J., Cottrell, C.E., Abel, H.J., Duncavage, E.J., Occult specimen contamination in routine clinical next-generation sequencing testing. Am J Clin Pathol 144 (2015), 667–674.
31. 31 Zook, J.M., Chapman, B., Wang, J., Mittelman, D., Hofmann, O., Hide, W., Salit, M., Integrating human sequence data sets provides a resource of benchmark SNP and indel genotype calls. Nat Biotechnol 32 (2014), 246–251.
32. 32 Eichler, H.G., Baird, L.G., Barker, R., Bloechl-Daum, B., Borlum-Kristensen, F., Brown, J., et al. From adaptive licensing to adaptive pathways: delivering a flexible life-span approach to bring new drugs to patients. Clin Pharmacol Ther 97 (2015), 234–246.